<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83036">
  <stage>Registered</stage>
  <submitdate>4/08/2008</submitdate>
  <approvaldate>22/08/2008</approvaldate>
  <actrnumber>ACTRN12608000414314</actrnumber>
  <trial_identification>
    <studytitle>Topical alkane vapocoolant spray versus subcutaneous lignocaine injection for reducing the pain of intravenous cannulation: a randomised, controlled, clinical trial</studytitle>
    <scientifictitle>A randomised clinical trial to compare the efficacy of pressurised vapocoolant spray and subcutaneous lignocaine injection in decreasing the pain of intravenous cannulation in the emergency department</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Pain of intravenous cannulation</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two second spray of pressurised vapocoolant 'Cold Spray' (butane, propane and pentane blend), from 12 cm, to the cannulation site. The alkane blend may vary with the batch and specific proportions of the three alkanes are not available.</interventions>
    <comparator>Subcutaneous injection of 0.2ml of plain 1% lignocaine local anaesthetic</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain score of intravenous cannulation (0-100) on a visual analogue scale</outcome>
      <timepoint>one minute after cannulation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Thrombophlebitis, blistering, frostbite, redness and swelling at the cannulation site</outcome>
      <timepoint>5 days after cannulation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Emergency department patients, aged 18 years or more, requiring intravenous cannulation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Refusal to provide consent
Inability to provide informed consent (Non-English speaking, altered mental state, significant illness, urgent need for IV cannulation)
Moderate to severe discomfort or pain
Diseases of the skin associated with cold intolerance (eg: Raynauds)
Known allergy to spray contents or lignocaine
Peripheral neuropathy
Parenteral analgesia in the previous 4 hours
Use of other local anaesthetics</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A note containing each individual patient's allocation will be inside a sealed envelope inside each study pack</concealment>
    <sequence>computer generated random number</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Due to difficulties in blinding the intervention and control, this will be an open study. The emergency department staff member cannulating the patient will administer either the vapocoolant spray or subcutaneous lignocaine, under the direction of a study investigator.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/10/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>220</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>Studley Rd
Heidelberg
Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Health</fundingname>
      <fundingaddress>Studley Rd
Heidelberg
Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Our previous research indicates vapocoolant is effective in significantly decreasing the pain of intravenous cannulation. This new study will compare vapocoolant with subcutaneous lignocaine, another common means of reducing the pain of cannulation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress>Studley Rd
Heidelberg
Victoria</ethicaddress>
      <ethicapprovaldate>31/10/2008</ethicapprovaldate>
      <hrec>not available at present</hrec>
      <ethicsubmitdate>20/08/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Studley Rd
Heidelberg
Victoria</address>
      <phone>03 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Studley Rd
Heidelberg
Victoria</address>
      <phone>03 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Studley Rd
Heidelberg
Victoria</address>
      <phone>03 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>